Abbott Gmbh & Co Kg

Abbvie Deutschland Gmbh and Co Kg

Abbvie Inc.

Herve Geneste

Liliane Unger

Wilfried Hornberger

Wilfried Lubisch

Wilfried Martin Braje

Thorsten K Oost

Wolfgang Wernet

Astrid Netz

Andreas Haupt

Daryl Richard Sauer

Andreas Kling

Udo Lange

Wilhelm Amberg

Karla Drescher

Roland Grandel

Charles W Hutchins

Sean Colm Turner

Berthold Behl

Michael Ochse

Mario Mezler

Katja Jantos

Marcel Van Gaalen

Arnulf Lauterbach

Loic Laplanche

Claudia Isabella Graef

Wilfred Braje

Silke Weber

Frank Oellien

Gerd Steiner

Werner Seitz

Thomas Subkowski

Margaretha Henrica Maria Bakker

Elizabeth Louise Van Der Kam

Andrea Hager-Wernet, Legal Representative

Ralf Biesinger

Jens Sadowski

Johann-Christian Zechel

Ana Lucia Jongen-Relo

Wilfred Lubisch

Thomas Subkoski

Jeroen Van Bergeijk

Patrick Walleser

Margaretha Henrica Bakker

The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

Fused heterocyclic compounds as S1P modulators

The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

Fused (hetero)cyclic compounds as S1P modulators

The present invention relates to novel substituted oxindole derivatives of formula (I), pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders. 

Oxindole derivatives carrying an oxetane substituent and use thereof for treating vassopressin-related diseases

The present invention relates to novel substituted oxindole derivatives of formula (I), pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders 

Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases

The present invention relates to heterocyclic compounds which are positive modulators of metabotropic glutamate receptor. The present invention also relates to the use of these compounds for preparing a pharmaceutical composition and to a method of treating a medical disorder, selected from neurological and psychiatric disorders associated with glutamate dysfunction.

Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor)

The invention relates to novel oxindole derivatives of general formula (I), wherein the substituents R, R, A, B, and Y are defined as in claim. The invention further relates to medicaments containing said derivatives, and use thereof for the prevention and/or treatment of vasopressin-dependent diseases. 

Substituted oxindole derivatives, medicaments containing said derivatives and use thereof

The present invention relates to novel oxindole derivatives of the general formula (I) to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent. 

Substituted oxindole derivatives and their use as vasopressin receptor ligands

The present invention relates to novel oxindole derivatives of the general formula (I) to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases.

The present invention relates to novel amidomethyl-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.

Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses

The present invention relates to novel carbamate-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.

Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases

The invention related to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Rwhich is/are selected, independently of each other, from halogen, CN, NO, COR, COR, C-C-alkyl and C-C-haloalkyl; Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R, which is/are selected from halogen, NO, CN, COR, COR, C-C-alkyl, C-C-alkenyl, C-C-alkynyl, C-C-cycloalkyl, C-C-cycloalkyl-C-C-alkyl and C-C-haloalkyl, with it also being possible for two radicals Rwhich are bonded to adjacent C atoms of Ar to be together C-C-alkylene; Ris hydrogen, C-C-alkyl, C-C-haloalkyl, C-C-cycloalkyl, C-C-cycloalkyl-C-C-alkyl, C-C-hydroxyalkyl, C-C-alkoxy-C-C-alkyl, C-C-alkenyl or C-C-alkynyl; with the radicals n, R, R, R, Rand Rhaving the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claimstoand/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine Dreceptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function. 

N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor

The present invention relates to novel oxindole derivatives of general formula (I), in which the substituents R, R, A, B and Y are as defined in claim, medicinal products containing them and use thereof for the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases.

Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands

The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R, R, R, R, and Rare defined according to claim, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.

Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them

The invention relates to tetrahydrobenzazepines of the general formula I in which the variables Ar, A, B, Y, Rand Rhave the meanings indicated in claim, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides. The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine Dreceptor antagonists or dopamine Dagonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.

[object Object]

The present invention relates to novel 4-piperazinylpyrimidine compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine Dreceptor. The 4-piperzinylpyrimidine compounds have the general formula I wherein Ar, X, A, Rand Rare as defined in the claims.

Growing community of inventors

Neuhofen, Germany

Herve Geneste